Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label,Dose-finding and Dose-expansion,Phase 1b Trial
1. Interdisciplinary Genitourinary Oncology, West-German Cancer Center, University Hospital Essen, Essen, Germany;2. Department of Urology, University Hospital Essen, Essen, Germany